Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOW: Blinatumomab + Chemotherapy in Newly Diagnosed Ph-negative B-ALL
NCT07564453Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Relapse-Free Survival at 2 years. Started Apr 2025; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07564453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07564453.